2022 SPIE and Photonics Media Prism Awards Celebrate Innovative Photonics Technologies
Earlier this evening, following a festive reception during SPIE Photonics West, SPIE, the international society for optics and photonics, and Photonics Media recognized the top optics and photonics products on the market with their industry-focused Prism Awards.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220126005964/en/
2022 SPIE and Photonics Media Prism Awards celebrate innovative photonics technologies at SPIE Photonics West. (Graphic: Business Wire)
The 14th annual ceremony showcased a dynamic range of companies — from Luxexcel, PlenOptika, and Lumotive, to SWIR, LightPath Technologies, and ColdQuanta — applying innovative and creative solutions to critical problems in areas such as augmented and virtual reality, biomedical devices, autonomous vehicles, quantum, and industrial lasers. In addition, the 2021 Prism Award winners of last year’s virtual ceremony were recognized in person at the beginning of the program.
Each year, the Prism Awards reflect the latest exciting developments, exponential growth, and rich technical innovations across photonics and photonics-enabled industries. For consideration in this year's awards, SPIE received 120 applications from 18 countries.
Finalists and winners were selected by a panel of international judges who leveraged the knowledge and acumen of leaders from across the technology commercialization and funding sectors. The distinguished judges’ roster included MKS Instruments’ Marc D. Himel, the FDA’s Zane Arp, Femto Blanc’s Uri Abrams, iFocus’ Adi Diner, Berkeley Catalyst Fund’s Laura Smoliar, Engender Technologies’ Cather Simpson, Luminate Accelerator’s Sujatha Ramanujan, Notal Vision’s Nishant Mohan, Teledyne Princeton Instruments’ Jason McClure, and Chromacity’s Shahida Imani.
"We are particularly delighted to be celebrating our Prism Award winners in person this year,” said SPIE CEO Kent Rochford. "These companies with their scientists and engineers — and I am including the award finalists as well — are ensuring that key technologies and products are reaching, energizing, and continually growing the photonics market. Their critical, innovative work is impacting lives across the globe.”
"Each year, the Prism Awards singles out the very brightest innovations in a highly innovative industry and, despite a global pandemic, supply chain issues, and other challenges over the past year, the 2022 winners still found a way to advance the field of photonics in important and remarkable ways,” said President and CEO of Photonics Media Tom Laurin. “We extend our congratulations to each of this year’s winners, who deserve our industry's recognition for their advancements in transportation, biomedicine, research, sensing, and quantum technology."
Below is the complete list of the award categories and the winners:
- Augmented & Virtual Reality: Luxexcel
- Autonomous Vehicles: Lumotive
- Better Sensing: SWIR Vision Systems
- Biomedical Devices: PlenOptika
- Displays: BRELYON
- Industrial Lasers: Civan Lasers
- Manufacturing & Test: LightPath Technologies
- Quantum: ColdQuanta
- Scientific Lasers: Stuttgart Instruments
- Software: Zemax
To find out more about the Prism Awards, please visit our website.
About Photonics Media
Photonics Media publishes print and digital business-to-business magazines, buyers' guides, websites, e-newsletters, webinars, virtual conferences, and podcasts for individuals working with light-based technologies in the photonics industry. A pioneering publisher in the discipline of photonics, Photonics Media has built a large global audience comprising academics and researchers, manufacturers, and end-users. Over the past six decades, the company has fostered a tradition of innovation that has defined the industry. As its publications grow — following the technology into an ever-widening range of applications — the company adheres to a philosophy of editorial quality and integrity, maintaining an international reputation for leadership in photonics. www.photonics.com.
SPIE, the international society for optics and photonics, brings engineers, scientists, students, and business professionals together to advance light-based science and technology. The Society, founded in 1955, connects and engages with our global constituency through industry-leading conferences and exhibitions; publications of conference proceedings, books, and journals in the SPIE Digital Library; and career-building opportunities. Over the past five years, SPIE has contributed more than $22 million to the international optics community through our advocacy and support, including scholarships, educational resources, travel grants, endowed gifts, and public-policy development. www.spie.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LintonPharm to Release Data on Catumaxomab for Advanced Gastric Cancer with Peritoneal Metastasis at 2022 ASCO Annual Meeting27.5.2022 15:00:00 CEST | Press release
LintonPharm Co., Ltd., a China-based biopharmaceutical company focusing on the development of T cell engaging bispecific antibodies for cancer immunotherapy, announces that preliminary results of Catumaxomab for advanced Gastric Cancer (GC) with peritoneal metastasis is published online at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Abstract Number：e16102 Abstract Title：Global multi-center phase I trial of the intraperitoneal infusion of anti-EpCAM x anti-CD3 bispecific antibody catumaxomab for advanced gastric carcinoma with peritoneal metastasis. The abstract is about the cohort A, stage I of the ongoing global phase Ⅲ trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis (clinicaltrials.gov: NCT04222114). Worldwide, GC is one of the most common cancers, contributing to more than 1 million cases per year and 5.6% of all cancer diagnoses . Approximately 50% of the advanced GC patients will develop p
FEELM unveils the world's first ceramic coil disposable pod solution at Vaper Expo UK 202227.5.2022 13:38:00 CEST | Press release
FEELM, the flagship atomization tech brand belonging to SMOORE, today showcased the world's first ceramic coil disposable pod solution series, FEELM Max at Vaper Expo UK 2022 in Birmingham, UK. By launching the solution and showcasing its cutting-edge ceramic coil heating technology, FEELM is introducing ceramic coil to the emerging category of disposable vape. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220527005197/en/ (Photo: Business Wire) As a new category in the ascendant, the disposable vape has been growing in popularity since 2020. The market size of disposable (closed system) vaping product has grown to approximately USD2.125 billion in 2021, accounting for 22.7% of global vaping device market share; and it is expected to increase at a GAGR of over 28% from 2022 to 2026, being the fastest-growing category among all vaping products, according to the estimates of Frost & Suvillian. In 2022, the market size of disp
Mavenir’s Containerized Open vRAN Small Cell Solution Wins Award for Outstanding Contribution to Emerging Technology or Architecture27.5.2022 09:00:00 CEST | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced to have won the SCF Small Cell Awards 2022 for Outstanding Contribution to Emerging Technology or Architecture, for its design and delivery of the first fully containerized small cell Open Virtualized Radio Access Network (Open vRAN), for indoor and outdoor connectivity. Mavenir’s containerized Open vRAN solution is a first of its kind and combines the interoperability of Open RAN with the portability and flexibility of containers. This small cell solution brings the same future-forward approaches of Open RAN and containerization having significant impacts in macro networks to small cell networks. The deployment of a containerized solution is a significant milestone in the evolution of connectivity, moving away from the physical infrastructure to a digital cloud-based environment. Containers take virtualizati
TYAN Brings Modern HPC Server Platforms for Data Centers at ISC 202227.5.2022 09:00:00 CEST | Press release
TYAN®, an industry-leading server platform design manufacturer and MiTAC Computing Technology Corporation subsidiary, will exhibit its latest HPC platforms powered by 3rd Gen AMD EPYC™ Processors with AMD 3D V-Cache™ technology for data centers deployments at the ISC 2022 event from May 30th to June 1st at booth #D400. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220527005002/en/ TYAN’s Server Platforms Powered by AMD EPYC 7003 Series Processors Provide the Best Foundation for Data Centers that Can be Tailored to Specific Workloads (Photo: Business Wire) “The amount of data generated by humans and machines has increased exponentially and this requires a steady increase of data center compute performance, therefore, modern data centers need balanced hardware to efficiently manage growing data volumes,” said Danny Hsu, Vice President of MiTAC Computing Technology Corporation's Server Infrastructure Business Unit. “TYAN’s ser
Takeda and Seagen to Highlight ADCETRIS ® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma26.5.2022 23:25:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502) and Seagen Inc., (NASDAQ:SGEN) today announced that overall survival (OS) data from the Phase 3 ECHELON-1 clinical trial of an ADCETRIS® (brentuximab vedotin) plus chemotherapy combination will be presented in an oral session at the 59th American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, June 3, 2022, 1:00-4:00 PM CT, and at the 27th European Hematology Association (EHA) Annual Meeting on Friday, June 10, 2022, 11:30 – 12:45 CEST. “The longer-term follow-up data from the ECHELON-1 trial have significant clinical importance, as this trial represents one of only two frontline randomized studies in advanced stage Hodgkin lymphoma that shows an overall survival advantage for the experimental arm,” said Stephen Ansell, M.D., Ph.D., Mayo Clinic, and ECHELON-1 study investigator. “These results clearly show that the addition of brentuximab vedotin to chemotherapy improves the long-term outcome of patients and the combination
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom